



## **Chuanhai Cao, Ph.D.**

University of South Florida, **Taneja College of Pharmacy**, Tampa, Florida

### **Address**

12901 Bruce B. Downs Boulevard, MDC 3013, Tampa, FL 33612  
Office: 813.396.0742  
Cellular: 813.368.0309  
Email: [ccao@usf.edu](mailto:ccao@usf.edu)

**Citizenship** USA

### **Education**

Biostatistics and Epidemiology (Public Health) Tianjin Medical University, M.S Tianjin, China	Sept 1990- June 1993
Medical Microbiology and Virology Tianjin Medical University, Ph.D, Tianjin, China	Sept 1993- June 1996

### **Postgraduate Training**

Postdoctoral Fellow Molecular Biology Nankai University, Tianjin, China	1996-1998
Postdoctoral Fellow, Cancer Biology Department of Pathology University of South Florida College of Medicine, Tampa, FL, USA	1998-1999
Postdoctoral Fellow, Immunology Department of Medical Microbiology and Immunology, University of South Florida College of Medicine, Tampa, FL, USA	1999-2002

### **Awards, Honors, Honorary Society Membership**

Certificate (Medical Doctor) Liaoning Health Department Liaoning, China	1988
Outstanding Postdoctoral Presentation University of South Florida College of Medicine Research Day Tampa FL, USA	1999
Outstanding Postdoctoral Presentation University of South Florida College of Medicine Research Day Tampa FL, USA	2000
Platinum Dean's Recognition Award University of South Florida College of Medicine and USF Health Tampa, FL, USA	2010
Outstanding Poster Award University of South Florida College of Medicine Research Day Tampa FL, USA	2010
Excellent Presenter Award American Physician Round Table Conference Tampa, FL, USA	2011
Token of Appreciation for Grant Submission Effort USF Research and Innovation Tampa, FL, USA	2013
Special Professor Award The First Affiliated Hospital of Dalian Medical University Tianjin, China	2013
Token of Appreciation for Grant Proposal Submission USF Research and Innovation Tampa, FL, USA	2013
Special Professor Award Tianjin Infectious Hospital Tianjin, China	2013
Plenary Talk Award International Conference on Complex Medical Engineering Taipei Taiwan	2014
Excellent in Innovation Award	2017

The 9 th NAI USF Chapter Sept 25th 2017 Tampa FL

Outstanding presentation 2018  
Florida Education Funds Midyear research and writing conference  
Tampa FL

## Appointments

**Science Research Investigator** 2018-date  
Department of Veterans Affairs  
Tampa, FL, USA

**Graduate Program** 2017-date  
Department of Chemistry  
University of South Florida  
College of Arts and Sciences,  
Tampa, FL, USA

**Associate Professor (Tenured)** 2016-date  
Department of Pharmaceutical Sciences  
University of South Florida College of Pharmacy  
Tampa, FL, USA

**Courtesy Associate Professor** 2016-date  
Department of Cell Biology, Microbiology, and Molecular Biology  
College of Arts & Sciences  
Tampa, FL, USA

**Courtesy Associate Professor** 2016-date  
Department of Neurology  
University of South Florida College of Medicine,  
Tampa, FL, USA

**Assistant Professor** 2015-2016  
Department of Neurology  
University of South Florida College of Medicine  
Tampa, FL, USA

**Courtesy Assistant Professor** 2013-2016  
Department of Cell Biology, Microbiology, and Molecular Biology  
University of South Florida College of Pharmacy  
Tampa, FL, USA

**Assistant Professor (Tenure Track)** 2011-2016  
Department of Pharmaceutical Sciences  
University of South Florida College of Pharmacy

Tampa, FL, USA

**Research Assistant Professor**

2008-2011

Department of Molecular Pharmacology and Physiology,  
University of South Florida College of Medicine,  
Tampa, FL, USA

**Research Investigator (Assistant Professor equivalent)**

2005-2008

USF Health Byrd Alzheimer's Institute  
Tampa, FL, USA

**Research Scientist**

2002-2005

Department of Medical Microbiology and Immunology  
University of South Florida College of Medicine  
Tampa, FL, USA

**Teaching, Lecture**

Pharmacotherapeutics II PHA 6783C (5 Credit) 2011-date

Pharmacotherapeutics III PHA 6784C (5 Credit) 2011-date

Molecular Principles of Drug Action PHA 6577 (4 Credit) 2011-date

PHA 6783C and PHA 6784C (Co-Course Coordinator) 2011-2018

Introduction for Principle of Drug Action PHA 6575 (3 Credit) 2019-date

PHA 6575 (Course Coordinator) 2019-date

**Committee for the Dissertation of PhD. Students:**

Statistical and Data Mining Methodologies for Behavioral  
Analysis in Transgenic Mouse 2009

Models of Alzheimer's Disease: Parallels with Human AD Evaluation  
Author: Ralph E. Leighty

Effects of G-CSF on Monocytes and Neurons:  
in vitro and in vivo studies in a Mouse 2012

<u>Model of Alzheimer's Disease</u> Author: Amanda Renee Pennington	
<u>The Inflammatory Response Initiated by the Spleen to Ischemic Stroke</u> Author: Hilary Seifert	2013
<u>Insights into [acute]-AA peptides and <math>\alpha</math>-AA peptides as broad spectrum antimicrobial peptidomimetics and as anti-biofilm agents</u> Author: Shruti Padhee	2014
<u>Design and Synthesis of Bioactive Peptidomimetics</u> Author: Yaogang Hu	2015
<u>Design, Synthesis and Applications of Polymer Biomaterials</u> Author: Frankie Costanza	2015
<u>Gamma AApeptides as Host Defense Peptide Mimics</u> Author: Yaqiong Li	2016
<u>Cell permeability studies of AApeptides and novel molecular probes for AD</u> Author: Ge Bai	2016
<u>New Reaction Discoveries in Gold Catalysis</u> Author: Seyedmorteza Hosseyni	2017

### **Visiting Scholars and Post-doctoral**

2011-2012 Zhe Zhang  
Associate Professor  
Shandong Chinese Traditional Medical University, Shandong, China

2011-2012 Fang Yuan  
Surgeon  
301 Hospital of the Chinese Military, Beijing, China

2012-2013 Yan Wang  
Associate Professor  
Tianjin Huanhu Hospital, Tianjin, China

2012 Yu Fu  
Assistant Professor  
Tianjin Infectious Hospital, Tianjin, China

2012 Srvadaman Pathak  
Visiting Scholar  
Sina-American Exchange Program  
Dalian Medical University, Dalian, China

2012-2013 Jie Qin  
Professor  
Tianjin Huanhu Hospital, Tianjin, China

2012-2013 Hui Lu  
Assistant Professor  
Tianjin Huanhu Hospital, Tianjin, China

2012-2013 Qi Li  
Director of Oncology and Professor  
Shuguang Hospital of Shanghai Traditional Medical University, Shanghai,  
China

2012-2013 Yuxia Hao  
Associate Professor  
Shanxi Provincial Hospital, Shanxi, China

2013-2014 Xiaozhen Zhao  
Associate Professor  
Nohua Hospital of Shanghai Traditional Medical University, Shanghai,  
China

2013-2014 Dong Lin  
Associate Professor  
Fuzhou Chinese Traditional Medical University, Fuzhou, China

2014-2015 Li Chu  
Associate Professor  
No. 10 Hospital of Shanghai, Shanghai, China

2014-2015 Jiang Chen  
Associate Professor  
Ningxia Medical University, Ningxia, China

2014-2015 Lifang Zhang  
Professor  
Ningxia Medical University, Ningxia, China

2015-2016 Jingwen Zhang

Assistant Professor  
Dalian Medical University Dalian, China

2015-2019 Yuzhu Hong  
Visiting Scholar  
Fuzhou Chinese Traditional Medical University, Fuzhou, China

**Committee member for Doctoral and Medical Students**

2009-2012 Ralph Leighty  
Department of Cell Biology, Microbiology, and Molecular Biology  
University of South Florida, Tampa, FL, USA

2009-2016 Ge Bai  
Doctoral Program in Chemistry  
University of South Florida, Tampa, FL, USA

2010-2016 Yaqiong Li  
Doctoral Program in Chemistry  
University of South Florida, Tampa, FL, USA

2010-2015 Seong Kim  
Doctoral Program in Chemistry  
University of South Florida, Tampa, FL, USA

2011-2017 Yaogang Hu  
Doctoral Program in Chemistry  
University of South Florida, Tampa, FL, USA

2011-2017 Sheshanka Kesani  
Doctoral Program in Chemistry  
University of South Florida, Tampa, FL, USA

2011-2017 Siqu Sun  
Doctoral Program in Chemistry  
University of South Florida, Tampa, FL, USA

2011-2015 Haifan Wu  
Doctoral Program in Chemistry  
University of South Florida, Tampa, FL, USA

2012-2016 Amanda Row  
Department of Neurology  
University of South Florida College of Medicine, Tampa, FL, USA

2012-2017 Qiao Qiao  
Doctoral Program in Chemistry  
University of South Florida, Tampa, FL, USA

2012-2018 Padmini Kavuru  
Doctoral Program in Chemistry  
University of South Florida, Tampa, FL, USA

2013-2017 Hilary Seifert  
Doctoral Program in Neuroscience  
University of South Florida College of Medicine, Tampa, FL, USA

2013-2018 Olapeju Oyesiku  
Doctoral Program in Chemistry  
University of South Florida, Tampa, FL, USA

2014-2017 Seongmin Hong  
Doctoral Program in Chemistry  
University of South Florida, Tampa, FL, USA

2015- 2018 Frankie Costanza  
Doctoral Program in Chemistry  
University of South Florida, Tampa, FL, USA

#### **Supervisor for Ph.D students**

2017 Ning Shen- date  
Doctoral Program in Chemistry  
University of South Florida College of Pharmacy, Tampa, FL, USA

2018 Haiqiang Yang- date  
Doctoral Program in Chemistry  
University of South Florida College of Pharmacy, Tampa, FL, USA

2018 Haohan Zhao- date  
Doctoral Program in Chemistry  
University of South Florida College of Pharmacy, Tampa, FL, USA

#### **Coach for Pharm D Students**

2015-2019 Nataliya Bynzar  
University of South Florida College of Pharmacy, Tampa, FL, USA

2015-2019 James Powers  
University of South Florida College of Pharmacy, Tampa, FL, USA



2015-2019 Erin Kennedy  
University of South Florida College of Pharmacy, Tampa, FL, USA

2015-2019 Benjamin Groves  
University of South Florida College of Pharmacy, Tampa, FL, USA

2015-2019 Saneeya Islam  
University of South Florida College of Pharmacy, Tampa, FL, USA

2015-2019 Lionel Ishikawa  
University of South Florida College of Pharmacy, Tampa, FL, USA

2015-2019 Shantel Houston  
University of South Florida College of Pharmacy, Tampa, FL, USA

2015-2019 David Bohunicky  
University of South Florida College of Pharmacy, Tampa, FL, USA

### **Master's Students**

2002 Sean Yoder  
Served as Master's thesis adviser  
University of South Florida, Tampa, FL, USA

2002 Susan Nyland  
Served as Master's thesis adviser  
University of South Florida, Tampa, FL, USA

2004 Nicole McCray  
Served as Master's thesis adviser  
University of South Florida, Tampa, FL, USA

2010 Alessandra Giannini  
Honors Program  
University of Miami Medical School, Miami, FL, USA

2011 Eileen Dabrowski  
Honors Program  
University of South Florida, Tampa, FL, USA

2014-2015 Kyle Sutherland  
Biomedical Master's Program  
University of South Florida, Tampa, FL, USA

## **Undergraduate Students**

2008-2011 Vignesh Chinnasamy  
University of South Florida, Tampa, FL, USA

2008-2011 Christine Dillingham  
Wake Forest Medical School, Winston-Salem, NC, USA

2010 Bill Xu  
University of Florida Medical School, Gainesville, FL, USA

2011-2012 Jugal Phanchal  
University of South Florida College of Pharmacy, Tampa, FL, USA

2011-2012 Neel Narba  
University of South Florida, Tampa, FL, USA

2012-2013 Joseph June  
Emory University, Atlanta, GA, USA

2012-2014 Jonathan Myal  
University of Central Florida Medical School, Orlando, FL, USA

2014-2016 Nikoa Skakavac  
University of South Florida, Tampa, FL, USA

2014-2016 Tyler D. Panzer  
University of South Florida, Tampa, FL, USA

2014-2016 Stephanie Hernandez  
University of South Florida, Tampa, FL, USA

2015-2016 Lawrence Guan  
University of South Florida, Tampa, FL, USA

2015-2016 Andrew Tran  
University of Illinois at Urbana-Champaign, Champaign, IL, USA

2015-2016 Armando Cabre  
University of South Florida, Tampa, FL, USA

2015-2017 Mario Cuzzi  
University of South Florida, Tampa, FL, USA

2015-2017 Sahar Takshi  
University of South Florida, Tampa, FL, USA

2015-2017 Adryan Perez  
University of South Florida, Tampa, FL, USA

2016-2018 Phillip Pham,  
University of South Florida, Tampa, FL, USA

2016-2018 Umer Khan,  
University of South Florida, Tampa, FL, USA

2017-2018 Adryan Perez  
University of South Florida, Tampa, FL, USA

### **Lectures by Invitation**

AD Treatment with Antigen Pulsed Dendritic Cells, NSF Byrd Institute 2006, Florida USA

Change in Plasma A $\beta$  Levels can be an early marker for AD treatment in PS1/APP Alzheimer's Mice models, International Conference Alzheimer's Disease 2006, Florida USA

New vaccine strategies against neurodegenerative diseases, USF Department of Cell Biology, Microbiology and Molecular Biology 2010, Florida USA

How to develop a safe and efficacy vaccine against Alzheimer's disease, USF Department of Pathology 2011, Florida USA

T-Cell Receptor Changes as a Biomarker of Parkinson's Disease, Michael J. Fox Foundation 2012, New York USA

The Therapeutic and prophylactic effects of coffee in Alzheimer's Disease 2012, National Taipei University of Technology, Taipei Taiwan

Alzheimer's disease and immune system, Ningxia Medical University 2014, YinChuan NingXia China

Medical Marijuana, Tianjin Huanhu Hospital 2015, Tianjin China

A Cell therapy targets A $\beta$  and modulates immune system for Alzheimer's Disease 2016, Beijing China

Immunotherapy of Parkinson's disease Tianjin Huanhu Hospital 2016, Tianjin China

A Safe and Efficacy Immunomodulatory Vaccine for Alzheimer's Disease, Jeffrey Vinik Funds 2017, Florida USA

The Impact of Coffee on Alzheimer's Disease, USF College of Pharmacy 2017, Florida USA

A Novel Cell based vaccine against Alzheimer's Disease, Spartan Capital 2017, New York USA

Understand the role of immune balance to AD and its treatment, Tampa Alliance Church 2017, Florida USA

Cannabinoids as a treatment for Alzheimer's Disease USF Department of Chemistry 2017, Florida USA

Medical Marijuana as a treatment for Alzheimer's Disease Department of Neurology Texas A&M 2017, Texas USA

THC as a treatment for Alzheimer's Disease, Baypine Veteran Hospital 2017, Florida USA

Understand the role of A $\beta$  in Alzheimer's disease, Chinese Alzheimer's Association 2018, Beijing China

Understand and Develop a treatment for Alzheimer's Disease Guided by Traditional Chinese Medicine, Jiaotong University 2019, Beijing China

### **Scholarly Activities (Grant History)**

#### **A) Current Grants**

Agency: NIH  
ID# R01AG056569  
Title: Gamma-AA peptides as novel biomaterials inhibiting Abeta peptide aggregation  
P.I: Jianfeng Cai, Ph.D  
Role on project: Multiple P.I  
Percent Effort: 15%  
Direct costs per year: \$250,000  
Total costs for project period: \$1,800,000  
Project period: July 2017–June 2022

Agency: NIH  
I.D# 9R01AI152416-06  
Title: Alpha-AA Peptides as a Novel Class of Antimicrobial Biomaterials  
P.I.: Jianfeng Cai, Ph.D

Role on Project: Co-Investigator  
Percent Effort: 8%  
Direct costs per year: \$300,000  
Total costs for project period: \$ 1,868,750  
Project period: May 2020– April 2025

Agency: MageNano Biotech Inc. (Florida High Tech Matching Fund)  
I.D# No ID  
Title: ***Immature peptide sensitized DC vaccine for prostate cancer***  
P.I.: Chuanhai Cao, Ph.D.  
Percent Effort: 6%  
Direct costs per year: \$20,000  
Total costs for project period: \$9500  
Project period: Oct 2020-Sept. 2021

B) Past Grants

Agency: NIH  
I.D# 1R01GM112652-01A1  
Title: Alpha-AA Peptides as a Novel Class of Antimicrobial Biomaterials  
P.I.: Jianfeng Cai, Ph.D  
Role on Project: Co-investigator  
Percent Effort: 8%  
Direct costs per year: \$200,000  
Total costs for project period: \$1,500,000  
Project period: May 2015-April 2020

Agency: NIH  
I.D# R01AG051500  
Title: Influence of systemic immune inflammation upon the tauopathy phenotype  
in a mouse model of tauopathy  
P.I.: David Morgan, Ph.D  
Role on Project: Co-investigator  
Percent Effort: 5%  
Direct costs per year: \$200,000  
Total costs for project period: \$1,500,000  
Project period: May 2015-April 2020

Agency: NIH SBIR  
ID# 1R43NS090653-01A1  
Title: Disaggregation of Toxic Protein Oligomers in Brain with  
Electromagnetic Treatment  
P.I.: Gary Arendash, Ph.D

Role on Project: Co-I  
Percent Effort: 12%  
Direct costs per year: \$225,000  
Total costs for project period: \$225,000  
Project period: Nov 2017-Oct 2018

Agency: NeuroEM Inc.  
I.D# No ID number  
Title: Cell phone Signal treatment for AD (clinical trial)  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 5%  
Total costs for project period: \$75,000  
Project period: Feb 2018-Jan 2019

Agency: Rhodes Pharmaceuticals L.P.  
I.D# No ID number  
Title: The Role of THC in AD, and nasal formulation for AD treatment  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 5%  
Direct costs per year: \$120,000  
Total costs for project period: \$323,528  
Project period: Dec 2015- Jan 2018

Agency: Insys Therapeutics Inc.  
I.D# No ID Number  
Title: The therapeutic efficacy of orally delivered THC in an Alzheimer's mouse model  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 20%  
Direct costs per year: \$100,000  
Total costs for project period: \$308,090  
Project period: 2015-April 2017

Agency: USF Health Intramural Zika Grant  
I.D# No ID Number  
Title: Develop a novel vaccine against Zika virus  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 5%  
Total costs for project period: \$40,000  
Project period: July 2017-June 2018

Agency: Coins for Alzheimer's Research Trust Fund  
I.D# No ID Number

Title: Oligomeric A $\beta$  nanoparticle sensitized dendritic cells as therapeutic  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 5%  
Total costs for project period: \$50,000  
Project period: Oct 2014-Sept 2015

Agency: Blume Family Donation  
I.D# No ID Number  
Title: Granulocyte colony stimulating factor (GCSF) therapy in patients  
with amyotrophic lateral sclerosis (ALS)  
P.I.: Vu Tuan, M.D.  
Role on Project: subcontract PI  
Percent Effort: 5%  
Total costs for project period: \$200,000  
Project period: Sept 2012- Aug 2015

Agency: Florida Consortium for AF - Suncoast Gerontology  
I.D# No ID Number  
Title: Florida Consortium for African-American Alzheimer's Disease Studies  
P.I.: Nilufer Ertekin-Taner MD Ph.D  
Role on Project: Co-I  
Percent Effort: 5%  
Total costs for project period: \$500,000  
Project period: Feb 2017-Jan 2019

Agency: USF Health/Byrd Institute Internal Grant  
I.D# No ID Number  
Title: Generating monoclonal antibody against Tau  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 5%  
Total costs for project period: \$25,000  
Project period: July 2014-June 2015

Agency: Florida Alzheimer's Disease Research Center  
I.D# No ID Number  
Title: Function of chlamydia Infection in Alzheimer's disease  
P.I.: Herman Fredman, Ph.D  
Role on Project: Co-I  
Percent Effort: 5%  
Total costs for project period: \$80,000  
Project period: July 2006-June 2007

Agency: Parkinson Research Foundation

I.D# No ID Number  
Title: Immunotherapy in Parkinson Disease  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 10%  
Total costs for project period: \$50,000  
Project period: Oct 2008-Sept 2009

Agency: BiTT Center at University of South Florida  
I.D# No ID Number  
Title: Metabolomics and mitochondrial proteomics of Alzheimer's mice  
P.I.: Patrick Bradshaw Ph.D  
Role on Project: Co-I  
Percent Effort: 5%  
Total costs for project period: \$50,000  
Project period: July 2009-June2010

Agency: The Michael J. Fox Foundation for Parkinson's Research  
I.D# No ID Number  
Title: T-cell receptor changes as a biomarker of Parkinson's disease  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 20%  
Total costs for project period: \$225,000  
Project period: July 2009-June 2012

Agency: Alzheimer's Drug Discovery Foundation  
I.D# No ID Number  
Title: Granulocyte-colony stimulating factor (GCSF) clinical study for Alzheimer's disease  
P.I.: Sanchez-Ramos, MD Ph.D  
Role on Project: Co-I  
Percent Effort: 5%  
Total costs for project period: \$300,000  
Project period: Sept 2009-Aug 2012

Agency: University of South Florida Women's Health Program  
I.D# No ID Number  
Title: Gender-linked stem cell alterations in stroke are magnified in postpartum depression: A target for neurorehabilitation.  
P.I.: Winderbaum Fernandez, Ph.D  
Role on Project: Co-I  
Percent Effort: 5%  
Total costs for project period: \$11,200



Project period: July 2013-June 2014

Agency: Veteran's Affairs Merit Grant  
I.D# No ID Number  
Title: Mechanisms of Action of Filgrastim in a Mouse Model of AD  
P.I.: Sanchez-Ramos, MD Ph.D  
Role on Project: Co-I  
Percent Effort: 10%  
Total costs for project period: \$750,000  
Project period: Sept 2009-Aug 2014

**Pending grants:**

Agency: NIH  
I.D# No ID Number  
Title: Phase II: Disaggregation of Toxic Protein Oligomers in Brain with  
Electromagnetic Treatment  
P.I.: Gary Arendash, Ph.D  
Role on Project: Co-PI  
Percent Effort: 10%  
Total costs for project period: \$2,000,000  
Project period: 09/01/2020-08/31/2022  
**(Impact Score:31)**

Agency: NIH  
I.D# R01AG066716  
Title: An Immunomodulatory Vaccine Against Aggregated A $\beta$  for Alzheimer  
Disease  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 20%  
Total costs for project period: \$3,284,308  
Project period: 9/01/2020-08/31/2025  
**(Impact Score: 59)**

Agency: NIH  
I.D# R01AG070057  
Title: Innovative Nasal Spray of THC-CBD Micelles as A Combinational  
Therapy for Alzheimer  
Disease  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 20%  
Total costs for project period: \$3,400,172  
Project period: 09/01/2020-08/31/2025

Agency: NIH  
I.D# R01AG071302  
Title: Novel peptide mimetics as potential AD therapeutics  
P.I.: Jianfeng Cai, Ph.D  
Role on Project: Multiple PI  
Percent Effort: 15%  
Total costs for project period: \$1,875,000  
Project period: 09/01/2020-08/31/2025

**Grants Submitted Since 2016 (Not Awarded)**

Agency: NIH  
I.D# 1R01AG062598-01  
Title: Polymer/Abeta nanomaterials for the intervention of AD  
P.I.: Jianfeng Cai Ph.D  
Role on Project: COI  
Percent Effort: 10%  
Total costs for project period:\$1,868,750.00  
Project period: 05/01/2019 - 04/30/2024

Agency: NIH  
I.D# R01AG059315  
Title: Combinational effects of intranasal delivery of THC and CBD in fighting Alzheimer's Disease  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 10%  
Total costs for project period:\$3,241,838.00  
Project period: 04/01/2018 - 03/31/2023

Agency: NIH  
I.D# R21AG053770  
Title: Validate a Therapeutic Vaccine Against Alzheimer's Disease on APP/PS1 mouse model  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 20%  
Total costs for project period:\$411,125.00  
Project period: 07/01/2016-06/30/2018

Agency: NIH

I.D# R21AI137901  
Title: Developing a peptide sensitized dendritic cells as a novel vaccine against the Zika virus  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 20%  
Total costs for project period:\$411,125.00  
Project period: 04/01/2018-03/31/2020

Agency: NIH  
I.D# R01AG054172  
Title: Association between Immunosenescence and Neurological Function in Alzheimer's disease  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 20%  
Total costs for project period: \$2,588,783.00  
Project period: 07/01/2016 - 06/30/2021

Agency: NIH  
I.D# R01NS100107  
Title: Antigen-specific Exosomes derived from Dendritic Cells as Therapeutics for Parkinson's disease  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 25%  
Total costs for project period: \$1,000,000.00  
Project period: 12/01/2016-11/30/2021

Agency: NIH  
I.D# R01AG054172  
Title: Association between Immunosenescence and Neurological Function in Alzheimer's disease  
P.I.: Chuanhai Cao, Ph.D  
Percent Effort: 25%  
Total costs for project period:\$2,588,783.00  
Project period: 07/01/2016-06/30/2021

### Publication Bibliography:

1. Viveros, M., Dickey, C., Cotropia, J.P., Gevorkian, G., Larralde, C., Broliden, K., Levi, M., Burgess, A., **Cao, C.**, Weiner, D.B., Agadjanyan, M.G., Ugen, K.E., 2000. Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41. *Virology* 270, 135–145.

2. Yoder, S., **Cao, C.**, Ugen, K.E., Dao, M.L., 2000. High-level expression of a truncated wall-associated protein A from the dental cariogenic *Streptococcus mutans*. *DNA Cell Biol.* 19, 401–408.
3. Dickey, C.A., Morgan, D.G., Kudchodkar, S., Weiner, D.B., Bai, Y., **Cao, C.**, Gordon, M.N., Ugen, K.E., 2001. Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide. *DNA Cell Biol.* 20, 723–729.
4. Han, T.K., Yoder, S., **Cao, C.**, Ugen, K.E., Dao, M.L., 2001. Expression of *Streptococcus mutans* wall-associated protein A gene in Chinese hamster ovary cells: prospect for a dental caries DNA vaccine. *DNA Cell Biol.* 20, 595–601.
5. Gómez-Román, V.R., **Cao, C.**, Bai, Y., Santamaría, H., Acero, G., Manoutcharian, K., Weiner, D.B., Ugen, K.E., Gevorkian, G., 2002. Phage-displayed mimotopes recognizing a biologically active anti-HIV-1 gp120 murine monoclonal antibody. *J. Acquir. Immune Defic. Syndr.* 31, 147–153.
6. Manoutcharian, K., Acero, G., Munguia, M.E., Montero, J.A., Govezensky, T., **Cao, C.**, Ugen, K., Gevorkian, G., 2003. Amyloid-beta peptide-specific single chain Fv antibodies isolated from an immune phage display library. *J. Neuroimmunol.* 145, 12–17.
7. Nyland, S.B., **Cao, C.**, Bai, Y., Loughran, T.P., Ugen, K.E., 2003. Modulation of infection and type 1 cytokine expression parameters by morphine during in vitro coinfection with human T-cell leukemia virus type I and HIV-1. *J. Acquir. Immune Defic. Syndr.* 32, 406–416.
8. **Cao, C.**, Bai, Y., Holloway, M.J., Edgeworth, R.L., Jackson, E.A., Cotropia, J., Ugen, K.E., 2004. Characterization of a novel human anti-HIV-1 gp41 IgM monoclonal antibody designated clone 37. *DNA Cell Biol.* 23, 836–841.
9. Ferrantelli, F., Kitabwalla, M., Rasmussen, R.A., **Cao, C.**, Chou, T.-C., Katinger, H., Stiegler, G., Cavacini, L.A., Bai, Y., Cotropia, J., Ugen, K.E., Ruprecht, R.M., 2004. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine. *J. Infect. Dis.* 189, 71–74.
10. Li, Q., **Cao, C.**, Chackerian, B., Schiller, J., Gordon, M., Ugen, K.E., Morgan, D., 2004. Overcoming antigen masking of anti-amyloid beta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloid beta immunized amyloid precursor protein transgenic mice. *BMC Neurosci.* 5, 21.
11. Manoutcharian, K., Acero, G., Munguia, M.E., Becerril, B., Massieu, L., Govezensky, T., Ortiz, E., Marks, J.D., **Cao, C.**, Ugen, K., Gevorkian, G., 2004. Human single

chain Fv antibodies and a complementarity determining region-derived peptide binding to amyloid-beta 1-42. *Neurobiol. Dis.* 17, 114–121.

12. Mccray, A; **Cao, C**; Muthumani, K; Weiner D, Ugen K; Richard Heller Regression of Established Melanoma Tumors through Intratumoral Delivery of HIV-1 Vpr Using In Vivo Electroporation Molecular Therapy, 2004, Vol.9(S1), p.S363

13. Ethell, D.W., Shippy, D., **Cao, C.**, Cracchiolo, J.R., Runfeldt, M., Blake, B., Arendash, G.W., 2006. Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. *Neurobiol. Dis.* 23, 351–361.

14. Gregson, B.P., Millie, D.F., **Cao, C.**, Fahnenstiel, G.L., Pigg, R.J., Fries, D.P., 2006. Simplified enrichment and identification of environmental peptide toxins using antibody-capture surfaces with subsequent mass spectrometry detection. *J. Chromatogr. A* 1123, 233–238.

15. Kutzler, M.A., **Cao, C.**, Bai, Y., Dong, H., Choe, P.Y., Saulino, V., McLaughlin, L., Whelan, A., Choo, A.Y., Weiner, D.B., Ugen, K.E., 2006. Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice. *Vaccine* 24, 4630–4639.

16. Bao, J., **Cao, C.**, Zhang, X., Jiang, F., Nicosia, S.V., Bai, W., 2007. Suppression of beta-amyloid precursor protein signaling into the nucleus by estrogens mediated through complex formation between the estrogen receptor and Fe65. *Mol. Cell. Biol.* 27, 1321–1333.

17. Li, Q., Gordon, M., **Cao, C.**, Ugen, K.E., Morgan, D., 2007. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. *BMC Neurosci.* 8, 22.

18. Lee, H., Kim, D., Dan, H.C., Wu, E.L., Gritsko, T.M., **Cao, C.**, Nicosia, S.V., Golemis, E.A., Liu, W., Coppola, D., Brem, S.S., Testa, J.R., Cheng, J.Q., 2007. Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein. *Mol. Cell. Biol.* 27, 2103–2119.

19. **Cao, C.**, Lin, X., Wahi, M.M., Jackson, E.A., Potter, H., 2008a. Successful adjuvant-free vaccination of BALB/c mice with mutated amyloid beta peptides. *BMC Neurosci.* 9, 25.

20. **Cao, C.**, Lin, X., Zhang, C., Wahi, M.M., Wefes, I., Arendash, G., Potter, H., 2008b. Mutant amyloid-beta-sensitized dendritic cells as Alzheimer's disease vaccine. *J. Neuroimmunol.* 200, 1–10.

21. Sanchez-Ramos, J., Song, S., **Cao, C.**, Arendash, G., 2008. The potential of

hematopoietic growth factors for treatment of Alzheimer's disease: a mini-review. *BMC Neurosci.* 9 Suppl 2, S3.

22. Arendash, G.W., Mori, T., **Cao, C.**, Mamcarz, M., Runfeldt, M., Dickson, A., Rezai-Zadeh, K., Tane, J., Citron, B.A., Lin, X., Echeverria, V., Potter, H., 2009. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. *J. Alzheimers Dis.* 17, 661–680.

23. **Cao, C.**, Arendash, G.W., Dickson, A., Mamcarz, M.B., Lin, X., Ethell, D.W., 2009a. Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. *Neurobiol. Dis.* 34, 63–70.

24. **Cao, C.**, Cirrito, J.R., Lin, X., Wang, L., Verges, D.K., Dickson, A., Mamcarz, M., Zhang, C., Mori, T., Arendash, G.W., Holtzman, D.M., Potter, H., 2009b. Caffeine suppresses  $\beta$ -amyloid levels in plasma and the brain of Alzheimer's transgenic mice. *J. Alzheimers Dis.* 17, 681–697.

25. Echeverria, V., Burgess, S., Gamble-George, J., Zeitlin, R., Lin, X., **Cao, C.**, Arendash, G.W., 2009. Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. *Neuroscience* 162, 1220–1231.

26. Olcese, J.M., **Cao, C.**, Mori, T., Mamcarz, M.B., Maxwell, A., Runfeldt, M.J., Wang, L., Zhang, C., Lin, X., Zhang, G., Arendash, G.W., 2009. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. *J. Pineal Res.* 47, 82–96.

27. Sanchez-Ramos, J., Song, S., Sava, V., Catlow, B., Lin, X., Mori, T., **Cao, C.**, Arendash, G.W., 2009. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. *Neuroscience* 163, 55–72.

28. Arendash, G.W., **Cao, C.**, 2010. Caffeine and coffee as therapeutics against Alzheimer's disease. *J. Alzheimers Dis.* 20 Suppl 1, S117–126.

29. Arendash, G.W., Sanchez-Ramos, J., Mori, T., Mamcarz, M., Lin, X., Runfeldt, M., Wang, L., Zhang, G., Sava, V., Tan, J., **Cao, C.**, 2010. Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice. *J. Alzheimers Dis.* 19, 191–210.

30. **Cao, C.**, Wang, L., Lin, X., Mamcarz, M., Zhang, C., Bai, G., Nong, J., Sussman, S., Arendash, G., 2011. Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer's mice. *J. Alzheimers Dis.* 25, 323–335.

31. Dragicevic, N., Bradshaw, P.C., Mamcarz, M., Lin, X., Wang, L., **Cao, C.**, Arendash, G.W., 2011. Long-term electromagnetic field treatment enhances brain mitochondrial function of both Alzheimer's transgenic mice and normal mice: a mechanism for electromagnetic field-induced cognitive benefit. *Neuroscience* 185, 135–149.
32. Dragicevic, N., Copes, N., O'Neal-Moffitt, G., Jin, J., Buzzeo, R., Mamcarz, M., Tan, J., **Cao, C.**, Olcese, J.M., Arendash, G.W., Bradshaw, P.C., 2011a. Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling. *J. Pineal Res.* 51, 75–86.
33. Dragicevic, N., Smith, A., Lin, X., Yuan, F., Copes, N., Delic, V., Tan, J., **Cao, C.**, Shytle, R.D., Bradshaw, P.C., 2011b. Green tea epigallocatechin-3-gallate (EGCG) and other flavonoids reduce Alzheimer's amyloid-induced mitochondrial dysfunction. *J. Alzheimers Dis.* 26, 507–521.
34. Niu, Y., Padhee, S., Wu, H., Bai, G., Harrington, L., Burda, W.N., Shaw, L.N., **Cao, C.**, Cai, J., 2011. Identification of  $\gamma$ -AApeptides with potent and broad-spectrum antimicrobial activity. *Chem. Commun.* 47, 12197–12199.
35. Padhee, S., Hu, Y., Niu, Y., Bai, G., Wu, H., Costanza, F., West, L., Harrington, L., Shaw, L.N., **Cao, C.**, Cai, J., 2011. Non-hemolytic  $\alpha$ -AApeptides as antimicrobial peptidomimetics. *Chem. Commun.* 47, 9729–9731.
36. Song, S., Sava, V., Rowe, A., Li, K., **Cao, C.**, Mori, T., Sanchez-Ramos, J., 2011. Granulocyte-colony stimulating factor (G-CSF) enhances recovery in mouse model of Parkinson's disease. *Neurosci. Lett.* 487, 153–157.
37. Bai, G., Padhee, S., Niu, Y., Wang, R.E., Qiao, Q., Buzzeo, R., **Cao, C.**, Cai, J., 2012. Cellular uptake of an  $\alpha$ -AApeptide. *Org. Biomol. Chem.* 10, 1149–1153.
38. **Cao, C.**, Loewenstein, D.A., Lin, X., Zhang, C., Wang, L., Duara, R., Wu, Y., Giannini, A., Bai, G., Cai, J., Greig, M., Schofield, E., Ashok, R., Small, B., Potter, H., Arendash, G.W., 2012. High blood caffeine levels in MCI linked to lack of progression to dementia. *J. Alzheimers Dis.* 30, 559–572.
39. Chen, X.-W., Sneed, K.B., Pan, S.-Y., **Cao, C.**, Kanwar, J.R., Chew, H., Zhou, S.-F., 2012. Herb-drug interactions and mechanistic and clinical considerations. *Curr. Drug Metab.* 13, 640–651.
40. Dragicevic, N., Delic, V., **Cao, C.**, Copes, N., Lin, X., Mamcarz, M., Wang, L., Arendash, G.W., Bradshaw, P.C., 2012. Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells. *Neuropharmacology* 63, 1368–1379.
41. Hu, Y., Amin, M.N., Padhee, S., Wang, R.E., Qiao, Q., Bai, G., Li, Y., Mathew, A.,

- Cao, C.**, Cai, J., 2012. Lipidated peptidomimetics with improved antimicrobial activity. *ACS Med. Chem. Lett.* 3, 683–686.
42. Luo, Z., Li, J., Nabar, N.R., Lin, X., Bai, G., Cai, J., Zhou, S.-F., **Cao, C.**, Wang, J., 2012. Efficacy of a therapeutic vaccine using mutated  $\beta$ -amyloid sensitized dendritic cells in Alzheimer's mice. *J. Neuroimmune Pharmacol.* 7, 640–655.
43. Nabar, N.R., Yuan, F., Lin, X., Wang, L., Bai, G., Mayl, J., Li, Y., Zhou, S.-F., Wang, J., Cai, J., **Cao, C.**, 2012. Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice. *PloS One* 7, e49468.
44. Niu, Y., Bai, G., Wu, H., Wang, R.E., Qiao, Q., Padhee, S., Buzzeo, R., **Cao, C.**, Cai, J., 2012a. Cellular translocation of a  $\gamma$ -AApeptide mimetic of Tat peptide. *Mol. Pharm.* 9, 1529–1534.
45. Niu, Y., Padhee, S., Wu, H., Bai, G., Qiao, Q., Hu, Y., Harrington, L., Burda, W.N., Shaw, L.N., **Cao, C.**, Cai, J., 2012b. Lipo- $\gamma$ -AApeptides as a new class of potent and broad-spectrum antimicrobial agents. *J. Med. Chem.* 55, 4003–4009.
46. Sanchez-Ramos, J., Cimino, C., Avila, R., Rowe, A., Chen, R., Whelan, G., Lin, X., **Cao, C.**, Ashok, R., 2012. Pilot study of granulocyte-colony stimulating factor for treatment of Alzheimer's disease. *J. Alzheimers Dis.* 31, 843–855.
47. Wu, H., Niu, Y., Padhee, S., Wang, R.E., Li, Y., Qiao, Q., Bai, G., **Cao, C.**, Cai, J., 2012. Design and synthesis of unprecedented cyclic  $\gamma$ -AApeptides for antimicrobial development. *Chem. Sci.* 3, 2570–2575.
48. Li, Y., Wu, H., Niu, Y., Hu, Y., Li, Q., **Cao, C.**, Cai, J., 2013. Development of RNA aptamer-based therapeutic agents. *Curr. Med. Chem.* 20, 3655–3663.
49. Niu, Y., Wu, H., Li, Y., Hu, Y., Padhee, S., Li, Q., **Cao, C.**, Cai, J., 2013. AApeptides as a new class of antimicrobial agents. *Org. Biomol. Chem.* 11, 4283–4290.
50. Selenica, M.-L.B., Alvarez, J.A., Nash, K.R., Lee, D.C., **Cao, C.**, Lin, X., Reid, P., Mouton, P.R., Morgan, D., Gordon, M.N., 2013. Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in the brain. *J. Neuroinflammation* 10, 86.
51. Song, S., **Cao, C.**, Lin, X., Li, K., Sava, V., Sanchez-Ramos, J., 2013. Hippocampal neurogenesis and the brain repair response to brief stereotaxic insertion of a microneedle. *Stem Cells Int.* 2013, 205878.
52. **Cao, C.**, Li, Y., Liu, H., Bai, G., Mayl, J., Lin, X., Sutherland, K., Nabar, N., Cai, J., 2014. The potential therapeutic effects of THC on Alzheimer's disease. *J. Alzheimers Dis. JAD* 42, 973–984.



53. Lin, X., Bai, G., Lin, L., Wu, H., Cai, J., Ugen, K.E., **Cao, C.**, 2014. Vaccination induced changes in pro-inflammatory cytokine levels as an early putative biomarker for cognitive improvement in a transgenic mouse model for Alzheimer disease. *Hum. Vaccines Immunother.* 10, 2024–2031.
54. Padhee, S., Smith, C., Wu, H., Li, Y., Manoj, N., Qiao, Q., Khan, Z., **Cao, C.**, Yin, H., Cai, J., 2014. The development of antimicrobial  $\alpha$ -AApeptides that suppress pro-inflammatory immune responses. *Chembiochem* 15, 688–694.
55. Costanza, F., Padhee, S., Wu, H., Wang, Y., Revenis, J., **Cao, C.**, Li, Q., Cai, J., 2014. Investigation of antimicrobial PEG-poly (amino acid)s. *RSC Adv.* 4, 2089–2095.
56. Lin, D., De La Pena, I., Lin, L., Zhou, S.-F., Borlongan, C.V., **Cao, C.**, 2014. The neuroprotective role of acupuncture and activation of the BDNF signaling pathway. *Int. J. Mol. Sci.* 15, 3234–3252.
57. Wu, H., Li, Y., Bai, G., Niu, Y., Qiao, Q., Tipton, J.D., **Cao, C.**, Cai, J., 2014.  $\gamma$ -AApeptide-based small-molecule ligands that inhibit A $\beta$  aggregation. *Chem. Commun.* 50, 5206–5208.
58. Cheng, J., Zhou, Z.-W., Sheng, H.-P., He, L.-J., Fan, X.-W., He, Z.-X., Sun, T., Zhang, X., Zhao, R.J., Gu, L., **Cao, C.**, Zhou, S.-F., 2015. An evidence-based update on the pharmacological activities and possible molecular targets of *Lycium barbarum* polysaccharides. *Drug Des. Devel. Ther.* 9, 33–78.
59. Li, Y; Smith, C; Wu, H; Teng, P; Shi, Y; Padhee, S; Jones, T; Nguyen, A; **Cao, C**; Yin, H; Cai, J. Short Antimicrobial Lipo- $\alpha/\gamma$ -AA Hybrid Peptides 2014 ChemBioChem, 13 October 2014, Vol.15(15), pp.2275-2280
61. Ugen, K.E., Lin, X., Bai, G., Liang, Z., Cai, J., Li, K., Song, S., **Cao, C.**, Sanchez-Ramos, J., 2015. Evaluation of an  $\alpha$  synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease. *Hum. Vaccines Immunother.* 11, 922–930.
62. Shahaduzzaman, M., Nash, K., Hudson, C., Sharif, M., Grimmig, B., Lin, X., Bai, G., Liu, H., Ugen, K.E., **Cao, C.**, Bickford, P.C., 2015. Anti-human  $\alpha$ -synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV- $\alpha$ -synuclein rat model of Parkinson's disease. *PLoS ONE* 10.
63. Chu, L., Zhao, H., Fang, J., Li, C., Liu, Z., Cui, R., Hu, F., Zhang, X., Chen, Y., Han, H., **Cao, C.**, Xu, Q., 2015. The traditional Chinese medicinal formula BDL301

suppresses tumor growth by inhibiting STAT3 pathway and inducing apoptosis in colorectal cancer cells. *DNA Cell Biol.* 34, 178–188.

64. Lin, D., Lin, L., Sutherland, K., **Cao, C.** 2015. Manual acupuncture at the SJ5 (Waiguan) acupoint shows neuroprotective effects by regulating expression of the anti-apoptotic gene Bcl-2. *Neural Regeneration Research*, 10(0).

65. Hao, Y., Bai, G., Wang, J., Zhao, L., Sutherland, K., Cai, J., **Cao, C.**, 2015. Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera. *BMC Immunol.* 16.

66. Li, Y., Wu, H., Teng, P., Bai, G., Lin, X., Zuo, X., **Cao, C.**, Cai, J., 2015. Helical antimicrobial sulfono- $\gamma$ -AApeptides. *J. Med. Chem.* 58, 4802–4811.

67. Lin, D., Wu, Q., Lin, X., Borlongan, C.V., He, Z.-X., Tan, J., **Cao, C.**, Zhou, S.-F., Brain-derived neurotrophic factor (BDNF) signaling pathway modulation by acupuncture in telomerase knockout mice. *Altern. Ther. Health Med.* 2015 Nov;21(6):36-46.

68. Cheng, J., Lin, X., Morgan, D., Gordon, M., Chen, X., Yang, X., Wang, Z., Li, H.-N., Zhou, S.-F., **Cao, C.**, The differential responses of dendritic and langerhans cells to A $\beta$  peptides stimulation and their implication in Alzheimer's Disease immunotherapy. *Oncotarget.* 2015 Nov 3;6(34):35443-35457.

69. Citron BA, Saykally JN, **Cao C**, Dennis JS, Runfeldt M, Arendash GW. Transcription factor Sp1 inhibition, memory, and cytokines in a mouse model of Alzheimer's disease. *Am J Neurodegener Dis.* 2015 Dec 28;4(2):40-8.

70. Tran A, Zhang CY, **Cao C**. Current and future therapies for Parkinson's disease. *J of Alz Dis and Parkinsonism.* 2015.

71. Perez A, Li T, Hernandez S, Zhang RY, and **Cao C**. The Rationale of using Coffee and Melatonin as Alternative Treatment for Alzheimer's disease. *J of Alz Dis and Parkinsonism.* Jan 2016, 6:205.

72. Perez A, Guan L, Sutherland K, and **Cao C**. Immune system and Parkinson's disease. *Arch Med.* Jan 2016, 8:2.

73. Lin X, Bai G, Sutherland K, Costanza F, Breitenkamp K, Sill K, Cai J, **Cao C**. Polymer-Encapsulated A $\beta$  Peptide Fragments as an Oligomeric-Specific Vaccine for Alzheimer's disease. *J. Biomed. Nanotechnol.*, 2016 Jul 12(7), 1421-1430.

74. Song S, Kong X, Sava V, **Cao C**, Acosta S, Borlongan C, Sanchez-Ramos J. Transient Microneedle Insertion into Hippocampus Triggers Neurogenesis and Decreases Amyloid Burden

in a Mouse Model of Alzheimer's Disease Cell Transplantation, Volume 25, Number 10, 2016, pp. 1853-1861(9)

75. Lin, L; Skakavac, N; Lin, X; Lin, D; Borlongan, M; Borlongan, C; **Cao, C**. Acupuncture-Induced Analgesia: The Role of Microglial Inhibition Cell Transplantation, April 2016, Vol.25(4), pp.621-628

76. Grewal R, Haghghi M, Huang S, Smith AG, **Cao C**, Lin X, Lee DC, Teten N, Hill AM, Selenica MB Identifying biomarkers of dementia prevalent among amnesic mild cognitively impaired ethnic female patients Alzheimers Res Ther. 2016 Oct 18;8(1):43.

77. Khan U and **Cao C**., Coffee Consumption Provides Therapeutic Benefits against AD through Increasing Plasma G-CSF Levels and Improving Cognitive Performance J Clin Neurol Neurosurg. 2018 Vol1:103

78. Shen N, Song G, Yang H, Lin X, Brown B, Hong Y, Cai J, **Cao C**. Identifying the Pathological Domain of Alpha- Synuclein as a Therapeutic for Parkinson's Disease Int J Mol Sci. 2019 May 11;20(9). pii: E2338.

79. **Cao C** and Brown B,. Understanding chinese medicine and western medicine to reach the maximum treatment benefit J Transl Sci, 2019.

80. Ratliff WA, Saykally JN, Mervis RF, Lin X, **Cao C**, Citron BA. Behavior, protein, and dendritic changes after model traumatic brain injury and treatment with nanocoffee particles BMC Neurosci. 2019 Aug 22;20(1):44.

81. Arendash G, **Cao C**, Abulaban H, Baranowski R, Wisniewski G, Becerra L, Andel R, Lin X, Zhang X, Wittwer D, Moulton J, Arrington J, Smith A. A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer's Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging J Alzheimers Dis. 2019 Aug 6.

82. Su, M., Wang, M., Hong, Y., Nimmagadda, A., Shen, N., Shi, Y., Gao, R., Zhang, E. **Cao, C.**, Cai, J. 2019. Polymyxin derivatives as broad-spectrum antibiotic agents. Chemical Communications, 55(87), 13104-13107.

83. Wang M, Gao R, Sang P, Zheng M, Shi Y, Xu H, **Cao C**, and Cai J,. Dimeric  $\gamma$ -AApeptides with Potent and Selective Antibacterial Activity Front. Chem. 2020|

84. Pocock K, Suresh N, Suradi Y, Dang S, Harvey B, **Cao C**, Sutherland K, Lin X, Vu TH, Gooch C. An Open-Label, Prospective Study Evaluating the Clinical and Immunological Effects of Higher Dose Granulocyte Colony-Stimulating Factor in ALS J Clin Neuromuscul Dis. 2020 Mar;21(3):127-134.

85. Shen N, and **Cao C**.. The comments to "The clinical trial of

EMF---the impact to cognition, CSF, blood and brain imagine” Chinese Journal of Alzheimer’s Disease and Related Disorders 2020 Jan 3 (1):46-47

86. Cao C. The comments to “Prevent AD through effective control to stroke”—Berlin Manistifo Chinese Journal of Alzheimer’s Disease and Related Disorders 2020 Jan Vol 3 (1);3

87. Song G, Yang H, Pham P, Brown B, Lin X, Hong Y, Sinu P, Cai J, Li X, Leon M, Gordon M, Morgan D, Zhang S, and Cao C. An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid Beta. J Alzheimers Dis. 2020. PMID: 32925044.

88. Chen Y, Yang JL, Xue ZZ, Cai QC, Hou C, Li HJ, Zhao LX, Zhang Y, Gao CW, Cong L, Wang TZ, Chen DM, LuoSQ, Yao Q, Zhu QS, Cao C Effects and mechanism of microRNA-218 against lung cancer Molecular Medicine Reports 2020 <https://doi.org/10.3892/mmr.2020.11666>

89. Shi-Yi Qi , Dong Lin , Li-Li Lin, Xiao-Zhen Huang , Shen Lin , Yun-Ying Yu, Chuan-Hai Cao ,and Zhi-Xin Wang Using Nonlinear Dynamics and Multivariate Statistics to Analyze EEG Signals of Insomniacs with the Intervention of Superficial Acupuncture Evidence-Based Complementary and Alternative Medicine Volume 2020, Article ID 8817843, 13 pages <https://doi.org/10.1155/2020/8817843>

90. Minesh Kapadia, M. Firoz Mian, Donglai Ma, Craig P. Hutton, Amber Azam, Klotilda Narkaj, Chuanhai Cao, Breanna Brown, Bernadeta Michalski, David Morgan, Paul Forsythe, Iva B. Zovkic, Margaret Fahnestock and Boris Sakic Differential effects of chronic immunosuppression on behavioral, epigenetic, and Alzheimer’s disease associated markers in 3xTg-AD mice Alzheimer's Research & Therapy (2021) 13:30 <https://doi.org/10.1186/s13195-020-00745-9>

(Purple color publications are published since being promoted to associate professor, Name with underline is correspondent author)

### Manuscripts Under Preparation

1. **Chuanhai Cao**, Xiaoyang Lin, Cai, J., Mayl, J., Huntington Potter, Liang, Z., Zhang, Morgan D. TCR clonality as early and stable biomarker for Alzheimer’s disease.

2. Yuzhu Hong, Breanna Brown, Xiaoyang Lin, Jiyu Yan, Haohan Zhao, Ning Shen Ping Chang, Marcia Gordon, David Morgan, **Chuanhai Cao** Intranasal low dose THC improved memory in AD mouse model

3. Ning Shen, Nanqi Liu, Breanna Brown, Xiaoyang Lin, Haohan Zhao, Haiqiang Yang Ping Chang, Jianfeng Cai, David Morgan, **Chuanhai Cao** Low dose THC delivered by intraperitoneal delay the memory impairment in AD mouse model

4. **Chuanhai Cao**, Xiaoyang Lin, Yuzhu Hong, Ning Shen, Yanhong Wang, Qishun Zhu, Wenshi Wang The innovative utilization of antigen sensitized dendritic cell as a powerful vaccine

5. **Chuanhai Cao**, Ning Shen, Xiaoyang Lin, Haohan Zhao, Haiqiang Yang,

Breanna Brown, Peng Teng, Bo Song, Yuzhu Hong, Jinsheng He, Ying Zhang, Xiaopeng Li and Jianfeng Cai Ratifying A $\beta$  as the pathological factor and therapeutic target for Alzheimer's disease

6. Lifang Zhang, Jessica Cao, Haiqiang Yang, Phillip Pham, Umer Khan, Breanna Brown, Yuzhu Hong, and **Chuanhai Cao**. The Quantity and Quality of Coffee for Alzheimer's disease

7. **Cao, C.**, Zesiekwiz, T., Li, Y., Lin, X., Li, F., Wang, W., Zhang, C., Bai, G., Cai, J., Mayl, J., Yuan, Z., Liang, Z., Zhang, P., Sanchez-Ramos, J. Peripheral blood as an early and stable biomarker for Parkinson's disease. Hum. Vaccines Immunother.

8. Ji-lin Yang, Hong-juan Li, Ying Zhang, Yan Chen , Cheng-wei Gao, Li Cong, Chun Hou, Tian-zuo Wang, Zhen-zhen Xue, Dong-mei Chen, Liu-xin Zhao, Guo-sheng Li 1 , Qian Yao, Chan-juan Yang, Qiu-chen Cai, Zhu Qi-shun, **Chuanhai Cao** Biological effects of artemether in the glioma cell line U251

#### **Books and Chapters in Books**

1. Nyland, S.B., **Cao, C.**, Ugen, K.E., 2002. Human T-cell lymphotropic virus types I and II, in: Rose, N.R., Hamilton, R.G., Detrick, B. (Eds.), Manual of Clinical Laboratory Immunology. American Society Microbiology, Washington, D.C, pp. 749–753.

2. **Cao, C.**, Ugen, K.E., Dickey, C., Wilcock, D., Bai, Y., Gordon, M.N., Morgan, D., 2012. Characterization of amyloid beta vaccination strategies in mice, in: Selkoe, D.J., Christen, Y. (Eds.), Immunization Against Alzheimer's Disease and Other Neurodegenerative Disorders, Research and Perspectives on Alzheimer's Disease. Springer Science & Business Media, pp. 21–32.

3. **Cao, C.**, Moore, T., Chu, L., 2014. Chapter 48: Coffee, granulocyte colony-stimulating factor (G-CSF), and neurodegenerative diseases, in: Preedy, V.R. (Ed.), Coffee in Health and Disease Prevention. Academic Press, pp. 435–442.

4. **Cao C.**, et al. Antioxidant Nutraceuticals : Preventive and Healthcare Applications (CRC Press 2018). ISBN9781351647342 (Editor)

5. **Cao C.**, et al. Chinese Terms In Alzheimer's disease. 2019  
ISBN 9787030616845

6. **Cao C.**, et al. Infectious & Non-Infectious Dementia. Prion & Alzheimer's.

#### **Peer-reviewed Abstracts**

1. **Cao, C.**, Lin, X., Zhang, C., Dillingham, C., Wang, L., Potter, H., 2008. Age-related changes in clonalities of T-cell receptor V $\beta$  repertoire within CD8 subsets, but not CD4, in healthy individuals. Presented at the American Association of Immunologists Conference, Miami, FL.
2. **Cao, C.**, Lin, X., Zhang, C., Dickson, A., Mamcarz, M., Wang, L., Arendash, G., Potter, H., 2008. Change of plasma A $\beta$  levels can be an early marker for AD treatment in PS1/APP Alzheimer's Mice model. Presented at the International Conference on Alzheimer's Disease, Chicago, IL.
3. Lin, X., Zhang, C., Potter, H., Breitenkamp, K., K, S., Christine, D., **Cao, C.**, 2008. Nanoparticle Alzheimer's disease vaccine targeting oligomeric A $\beta$ . Presented at the International Conference on Alzheimer's Disease, Chicago, IL.
4. Sanchez-Ramos, J., Song, S., **Cao, C.**, Lin, X., Mori, T., Arendash, G., 2008. Granulocyte-colony stimulating factor reduces hippocampal amyloid load And Improves behavioral performance in a transgenic Alzheimer's disease mouse model. Presented at the International Conference on Alzheimer's Disease, Chicago, IL.
5. Olcese, J.M., Mori, T., Dorsey, M.B., **Cao, C.**, Arendash, G.W., 2008. Melatonin lowers brain  $\beta$ -amyloid load and reduces cognitive loss in a transgenic model of Alzheimer dementia. Presented at the Society for Neuroscience Conference, Washington, DC.
6. Wang, L., Lin, X., Zhang, C., Potter, H., Arendash, G., **Cao, C.**, 2008. The non-caffeine constituents of coffee to do interfere with caffeine's ability to reduce blood A $\beta$  levels in Alzheimer's transgenic mice. Presented at the Society for Neuroscience Conference, Washington, DC.
7. Ethell, D., **Cao, C.**, Dickson, A., Mamcarz, M.B., Lin, X., Arendash, G., 2009. Cognitive and pathological benefits of A $\beta$ -sensitive Th2 cells are independent of antigen-specific B cell activation. Presented at the International Conference on Alzheimer's Disease, Copenhagen, Denmark.
8. **Cao, C.**, Lin, X., Wang, M., Mamcarz, M., Runfeldt, M., Arendash, G., 2009. The therapeutic effects of caffeine and coffee in Alzheimer's disease. Presented at the Society for Neuroscience Conference, Chicago, IL.
9. Song, S., Catlow, B., Li, K., Sava, V., **Cao, C.**, Arendash, G., Sanchez-Ramos, J., 2009. Promotion of brain self-repair mechanisms by stereotaxic micro-lesions. Presented at the Society for Neuroscience Conference, Chicago, IL.
10. Arendash, G., Sanchez-Ramos, J., Mori, T., Dorsey, M.B., Wang, L., Lin, X., Bradshaw, P.C., Dragicevic, N., **Cao, C.**, 2010. Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's mice Alpha

synuclein peptide sensitized dendritic cells as a vaccine against Parkinson's disease. Presented at the Society for Neuroscience Conference, San Diego, CA.

11. **Cao, C.**, Lin, X., Wang, M., Song, S., Bai, G., Li, F., Sanchez-Ramos, J., 2010. Alpha synuclein peptide sensitized dendritic cells as vaccine against Parkinson's disease. Presented at the Society for Neuroscience Conference, San Diego, CA.

12. O'Neal-Moffitt, G., Patel, A., **Cao, C.**, Bradshaw, P.C., Lin, X., Olcese, J.M., 2010. Melatonin has neuroprotective actions in a cellular model of Alzheimer's disease. Presented at the Society for Neuroscience Conference, San Diego, CA.

13. Bai, G., Padhee, S., Niu, Y., Wang, R.E., Buzzeo, R., **Cao, C.**, Cai, J., 2011a. Unexpected enhanced cellular uptake of a  $\alpha$ -AApeptide. Presented at the USF Health, Tampa, FL.

14. Bai, G., Zesiekwiz, T., Lin, X., Li, F., Wang, W., Zhang, G., Zhang, C., Cai, J., Yuan, Z., Zhang, P., Sanchez-Ramos, J., **Cao, C.**, 2011b. Biomarkers in peripheral immune system for Parkinson's disease. Presented at the USF Health, Tampa, FL.

15. **Cao, C.**, Zesiekwiz, T., Lin, X., Li, F., Wang, W., Zhang, G., Bai, G., Cai, J., Sanchez-Ramos, J., 2011. T-cell receptor change as an early and stable biomarker for Parkinson's disease. Presented at the Society for Neuroscience Conference, San Diego, CA.

16. Zhang, Z., **Cao, C.**, Bai, G., Zhou, S., 2011. The effect of natural compounds on signal pathway of Alzheimer's disease. Presented at the Society for Neuroscience Conference, San Diego, CA.

17. **Cao, C.**, Lin, X., Raj, A., Wang, W., Li, Y., Cai, J., Potter, Huntington, 2012. The role of CD8 T-cell and its receptor change in Alzheimer's disease. Presented at the Alzheimer's Association International Conference, Vancouver, Canada.

18. Bai, G., Lin, X., Li, Y., Wu, H., **Cao, C.**, 2012. The molecular mechanism study of melatonin on Alzheimer's Disease. Presented at the Society for Neuroscience Conference, New Orleans, LA.

19. Li, Y., **Cao, C.**, Cai, J., 2012. Redefining the mechanism of tetrahydrocannabinol (THC) against Alzheimer's Disease. Presented at the Society for Neuroscience Conference, New Orleans, LA.

20. Pathak, Y., Andrisk, R., Lin, X., **Cao, C.**, 2013. Development of a novel vaccine using nanoemulsion against neurodegenerative diseases. Presented at the BioFlorida, West Palm Beach, FL.

21. Bai, G., Wu, H., Li, Y., Niu, Y., Qiao, Q., Lin, X., Cai, J., **Cao, C.**, 2013. Anti-

aggregation effect of AA-peptide on  $\beta$ -Amyloid peptides in Alzheimer's diseases. Presented at the USF Health, Tampa, FL.

22. Sutherland, K., Dix, M., Lin, X., Bai, G., Liu, H., **Cao, C.**, 2013. Distinct differences of T-cell receptor V $\beta$  chains clonality and other markers between Parkinson's disease and Alzheimer's disease. Presented at the USF Health, Tampa, FL.

23. **Cao, C.**, Wu, H., Li, Y., Niu, Y., Qiao, Q., Lin, X., Cai, J., 2013. Anti-aggregation effect of AA-peptide on  $\beta$ -Amyloid peptides in Alzheimer's diseases. Presented at the Society for Neuroscience Conference, San Diego, CA.

24. Shaduzzaman, M., Nash, K., Hudson, C., Grimmig, B., Lin, X., Bai, G., Liu, H., **Cao, C.**, Bickford, P.C., 2013. Anti- $\alpha$ -synuclein antibodies provide neuroprotection and reduce behavioral deficits in a rat AAV9- $\alpha$ -synuclein model of Parkinson's disease. Presented at the Society for Neuroscience Conference, San Diego, CA.

25. Vu, T.H., McClain, T., **Cao, C.**, Tucker, N., Harvey, B., Katzin, L., Gooch, C., 2014. Pilot trial of high frequency high dose granulocyte colony stimulating factor (GCSF) in patients with amyotrophic lateral sclerosis (ALS). Presented at the American Academy of Neurology Conference, Philadelphia, PA.

26. P. Pham, X. Lin, Y. Hong, B. Brown, J. Cai, **C. Cao.**, 2017. The novel vaccine targeting oligomeric amyloid beta with immunomodulatory effects. Presented at the Society for Neuroscience, DC USA

27. H. Yang, **C. Cao**, P. Pham. U. Khan, Y. Hong, X Lin, N. Shen., 2018. The *in vitro* effect of different coffees and extraction of coffee in Alzheimer's disease-associated cell line. Presented at the Society for Neuroscience, San Diego CA

28. **C. Cao**, X. Lin, Y. Hong, B. Brown, J. Cai. A., 2019. Mutant Beta Amyloid Sensitized Cells As An Oligomeric Specific Vaccine Against APP. Presented at the AD/PD meeting, Lisbon, Portugal.

29. **Cao, C.**, Lin. X, Y. Hong, B. Brown, J. Cai., 2019. The Rationale of Mutated Amyloid Beta Sensitized Dendritic Cells As a Therapeutic Vaccine for Alzheimer's Disease. Presented at the Alzheimer's Association International Conference, Los Angeles CA.

## Other Research and Creative Achievements

### Awarded Patents:

1. Ugen, K.E., Specter, S., Nyland, S.B., **Cao, C.**, 2011. Anti-activity of the opioid antagonist naloxone. U.S. Patent No. 8,067,430



2. [Cao, C., 2012. Amyloid beta peptides and methods of use. U.S. Patent No. 8,188,046 \(Licensed by Alzamend Neuro Inc\) \*\*Awarded: \\$400,000\*\*](#)
3. [Cao, C., Lin, X., Potter, H., 2013. Method of diagnosing or assessing risk for Parkinson's disease or Alzheimer's disease using TCR clonality. U.S. Patent No. 8,383,347](#)
4. [Arendash, G.W., Cao, C., Tan, J., 2016. Prevention and treatment of Alzheimer's disease through electromagnetic field exposure. U.S. Patent No. 9,238,149 \(Licensed by NeuroEM Inc. Arizona USA\) \*\*Awarded: \\$60,000\*\*](#)
5. [Jianfeng Cai, Cao, C., Wu H., Li Y., Bai Ge., 2018. Methods of synthesizing  \$\gamma\$ -AApeptides,  \$\gamma\$ -AApeptide building blocks,  \$\gamma\$ -AApeptide libraries, and  \$\gamma\$ -AApeptide inhibitors of A \$\beta\$ 40 aggregates. U.S. Patent No. 10,022,420.](#)
6. [Cao, C., Lin, X., 2018. Methods of using a transgenic nonhuman animal in an in vivo test method. U.S. Patent No. 10,155,030.](#)
7. [Jianfeng, Cai, Cao, C., 2020. Compounds for the treatment of neurodegenerative diseases. U.S. Patent No. 10,538,553](#)

### **Pending Patents:**

1. [Cao, C., Lin, X., Breitenkamp, K., Skaff, H., Sill, K.N., 2014. Immunotherapy for treatment of amyloid-related disorders using encapsulated beta-amyloid peptides. USF Ref. No. 20140170225 A1.](#)
2. [Cao, C., 2015. THC as a potential therapeutic agent for Alzheimer's disease. USF Ref. No. 15A089PR. \(Licensed by IGC Inc. Maryland USA\) - \*\*Awarded: \\$250,000\*\*](#)
3. [Cai, J., Cao, C., 2019. Novel compounds for the treatment of neurodegenerative diseases. USF Ref. No. 20190211059](#)
4. [Cao C., 2018 The Dead Antigen Stimulated Immature Heterogeneous Dendritic Cell as Therapeutics for Diseases USF Ref. No.: 17A067PR \(Licensed by MegaNano BioTech Inc. Tampa USA\) - \*\*Awarded: \\$6,000\*\*](#)
5. [Cao C., 2020 The combinational intranasal formula using Melatonin, Insulin and THC \(MIT\) as therapeutic for AD. USF Ref. No. 20A115](#)
6. [Cao C. and Jianfeng Cai 2020 A novel sulfono- \$\gamma\$ -AApeptides as potential treatment for neurological disease and promote neuron generation \(filing number is pending\)](#)
7. [Cao, C., and Chang P Cannabinoid compositions and dosage forms for intranasal or inhalation delivery. Application No. 63030083](#)

### **Service**

### **Grants reviewer**

Alzheimer's Association  
Grant Reviewer 2005- date

NIH AD Clinical Trials Review Panel 2020- date  
Early and Late stage Clinical Trials for the  
Spectrum of Alzheimer's Disease and Age-related Cognitive Decline  
Grant Reviewer

NIH The Chronic Dysfunction and Integrative Neurodegeneration study section (CDIN) 2020 -Date  
Grant Reviewer

Israel Science Foundation (ISF) 2017  
Grant Reviewer

RR&D Scientific Merit Review Board 2017  
Grant Reviewer

Velux Stiftung Zürich 2018-date  
Switzerland  
Grant Reviewer

### **Scientific Journals**

BMC Neuroscience 2008-date  
Peer reviewer

Vaccine 2008-date  
Peer reviewer

Neurobiology of Aging 2010-date  
Peer reviewer

Journal of Anatomy 2011-date  
Peer reviewer

PLOS ONE 2011-date  
Peer reviewer

Canadian Medical Association Journal 2012-date  
Peer reviewer

Human Vaccines and Immunotherapeutics 2012-date  
Peer reviewer

Journal of Molecular and Cell Biology Peer reviewer	2012-date
Cellular and Molecular Immunology Peer reviewer	2013-date
Journal of Visualized Experiments Peer reviewer	2013-date
Journal of Nutritional Biochemistry Peer reviewer	2013-date
Neurobiology of Aging Peer reviewer	2013-date
SOJ Neurology Editorial Board Member	2013-date
Journal of Alzheimer's Disease Associate Editor Peer reviewer	2014-date
SOJ Immunology Editorial Board Member	2015-date
Advances in Medicine Editorial Board Member	2015-date
SM Vaccines and Vaccination Journal Editorial Board Member	2015-date
Chinese Dementia and Associated Neurological Disorders Associate Editor and Board Member	2018-date

**Society Memberships**

Society for Neuroscience Member	2005-date
American Association of Immunologists Member	2006-date

Florida Alzheimer Disease Research Center  
Research Investigator 2006- date

Florida Center of Excellence for Drug Discovery and Innovation  
Member 2007- date

China Committee For Alzheimer's Disease International  
Member, Scientific and Technological Advisory Board 2008- date

National Academy of Inventors  
Member 2014- date

China Association for Alzheimer's Disease  
Member, Senior Advisory Board 2015- date

GuidePoint  
Neuromuscular and Autoimmune Expertise  
Member 2019-date

### **Academic Committees**

#### **International**

First Congress of China Association for Alzheimer's Disease  
Senior Advisory Board Member 2015

China Alzheimer's Disease Neuroimaging Initiative  
Scientific Advisory Board Member 2008-date

Alzheimer's Disease International  
Scientific Advisory Board Member 2008-date

### **University of South Florida**

University of South Florida Asian Alliance  
President 2013-date

USF-Health Neuroscience Institute  
Member 2018- date

University of South Florida  
Faculty Senate Committee  
Member 2019- date

**College of Pharmacy**

Curriculum Committee University of South Florida, Taneja College of Pharmacy Member	2012-2014
Bylaws Committee University of South Florida, Taneja College of Pharmacy Member	2012-2014
Committee on Research University of South Florida, Taneja College of Pharmacy Member	2012-2016
International Affairs Committee University of South Florida, Taneja College of Pharmacy Member	2013-2016
Biosafety Committee University of South Florida, Taneja College of Pharmacy Member	2014-2017
Master's Program Committee University of South Florida, Taneja College of Pharmacy Member	2015-2019
University of South Florida Taneja College of Pharmacy Admissions Committee Member	2015-2019
University of South Florida Taneja College of Pharmacy Tenure and promotion committee Member	2016-2019
University of South Florida Taneja College of Pharmacy Academic Review Committee Member	2016-date